PITTSBURGH–(BUSINESS WIRE)–Noveome Biotherapeutics, Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has appointed Ronald K. Poropatich, M.D., M.S., to the company’s Board of Directors.
Dr. Poropatich is an experienced Pulmonary/Critical Care Medicine physician-scientist who serves as the Director of the Center for Military Medicine Research (CMMR), Health Sciences and Professor of Medicine in the Division of Pulmonary, Allergy, and Critical Care Medicine at the University of Pittsburgh. The University of Pittsburgh CMMR has been instrumental in building collaborative multi-disciplinary and multi-organizational research teams to improve the health and well-being of service members, veterans and their families that has led to significant DoD medical research collaboration with the University of Pittsburgh . Dr. Poropatich has also been on the faculty at the Uniformed Services University of the Health Science (USUHS) since 1985 and currently serves as an Adjunct Professor of Medicine. Dr. Poropatich served 30 years on active duty in the U.S. Army retiring in 2012 at the rank of Colonel with extended assignments at the Walter Reed National Military Medical Center (1985 to 2012) and the US Army Medical Research and Development Command (2006-2012).
“We are delighted to welcome Dr. Poropatich to our Board of Directors. He brings a wealth of medical experience from both his long career in the U.S. Army as well as his post-military achievements at the University of Pittsburgh,” said William Golden, Founder, Chairman and CEO of Noveome.
Dr. Poropatich received his medical degree from Drexel University in 1985. He completed his internship and residency in Internal Medicine at Walter Reed in 1988 and his fellowships in Pulmonary and Critical Care Medicine at the Walter Reed in 1992. His career includes a strong clinical foundation coupled with managing large medical research programs and expansion of telemedicine across 22 time zones to meet the global Army medical need for peacetime and wartime settings.
“I’m excited to join the Noveome board, especially at this pivotal time in the company’s history. The vast potential of its multi-targeted secretome, ST266, in systemic inflammation is very compelling for a variety of clinical applications,” said Dr. Poropatich. “I look forward to working with the Noveome team to improve clinical outcomes in a range of complex diseases.”
About ST266
ST266 is a cell-free biologic made by culturing a novel population of human amnion-derived cells. Through a proprietary culturing method, these cells produce an array of growth factors and cytokines, known as the secretome, which promote cellular survival and reduce inflammation.
About Noveome Biotherapeutics, Inc.
Based in Pittsburgh, Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome has launched a program to test its novel platform biologic, ST266, as a treatment for the severe inflammatory response seen in COVID-19 infection as well as the post-COVID-19 symptoms experienced by many COVID-19 patients. Noveome has completed a Phase 2 open-label clinical trial that demonstrated the benefit ST266 had in healing persistent corneal epithelial defects (PEDs). ST266 is also being evaluated in a Phase 1 open label clinical trial to establish the safety of ST266 in intranasal transcribriform delivery from nose to brain and eye. Noveome is currently planning follow-up clinical studies to characterize the efficacy and safety of ST266 further for the treatment of PEDs and a Phase 1 study evaluating the safety of intravenously administered ST266 in COVID-19 patients. For more information, visit www.noveome.com.
Contacts
Erik Clausen
CG Life
781-608-7091
noveome@cglife.com